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A PUBLIC HEALTH PERSPECTIVE
ON THE CONTROL OF
PREDICTIVE SCREENING FOR
BREAST CANCER
George C. Cunningham, M.D., M.P.H.t
AS A PUBLIC HEALTH PROFESSIONAL, the per-
spectives that I bring in response to this new and challenging
technology encompass two interests: one is disease prevention,
and the other is protection of the public. My general approach
is best summarized by the philosophy expressed in the title of
Neil A. Holtzman's book, Proceed with Caution.'
The definition of the word "proceed" within the public
health context allows the public to enjoy the considerable prov-
en benefits of a new technology in a reasonable period of time.
Likewise, within this same context, "caution" allows the deter-
mination that the benefits of employing technology exceed
adverse consequences. Likewise, that the methods used in
application of the technology minimize the potentially adverse
consequences.
It is clear at the outset, that nature provides no free lunch.
Every change in the health care environment has both short
and long-term consequences, intended and unintended, antici-
pated and unanticipated. Additionally, it is also clear that
health care will never be static. Change will inevitably occur.
Withholding action in any setting, and particularly in the
t B.S., University of San Francisco; M.D., University of California, Los Angeles;
M.P.H., University of California, Berkeley. Dr. Cunningham is currently principal investigator of
the Pacific Southwest Regional Genetics Network and delegate to the Council of Regional
Networks for Genetics Services.
1. NEIL A. HOLTZMAN, PROCEED WITH CAUTION: PREDICTING GENETIC RISKS IN THE
RECOMBINANT DNA ERA (1989) (supporting the author's premise that caution is necessary in the
genetic era).
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public health context, is a choice which also has consequences.
Thus, our primary task must be to control the rate and direc-
tion of change. Denying benefits until every potential adverse
consequence is scientifically addressed and knowledge is com-
plete and certain is not morally or pragmatically defensible.
Any public health policy must be made on a population basis
and therefore cannot be optimal for every individual in the
population. The task in public health is to adopt policies which
guide these changes in a direction that will produce the greatest
good for the greatest number of individuals.
We now have new and important information about the
relationship between genes and breast cancer.2 This informa-
tion is a vital contribution to understanding the disease process.
However, we are far from having definitive answers. The infor-
mation is incomplete and generates many questions for which
we do not have satisfactory answers? This Article will outline
my seven-step analysis of the role for federal and/or state pub-
lic health agencies in responding to this conundrum. To preface
my position, I agree with the position espoused by Neil A.
Holtzman,4 Benjamin S. Wilfond, Kathleen Nolan5 and others,
2. See generally Amelia A. Langston et al., BRCAI Mutations in a Population-Based
Sample of Young Women With Breast Cancer, 334 NEw ENG. J. MED. 137 (1996) (discussing
findings from DNA samples from eighty women enrolled in a population-based study of early-
onset breast cancer to assess the spectrum and frequency of germ-line BRCAI mutations);
Richard Wooster et al., Localization of a Breast Cancer Susceptibility Gene, BRCA2, to
Chromosome 13q12-13, 265 ScIENcE 2088 (1994) (discussing evidence that suggests that
BRCA2 confers a high risk of breast cancer but, unlike BRCA1, does not confer a substantially
elevated risk of ovarian cancer); Michael G. FitzGerald et al., Germ-Line BRCAI Mutations in
Jewish and Non-Jewish Women with Early-Onset Breast Cancer, 334 NEw ENG. J. MED. 143
(1996) (finding that germ-line BRCA1 mutations can be present in young women with breast
cancer who do not belong to families with multiple affected members); Donna Shattuck-Eidens et
al., A Collaborative Survey of 80 Mutations in the BRCAI Breast and Ovarian Cancer
Susceptibility Gene: Implications for Presymptomatic Testing and Screening, 273 JAMA 535
(1995) (discussing the necessity for more data to be accumulated to address the sensitivity and
specificity of a BRCA 1 diagnostic testing procedure and to better estimate the age-specific risk for
breast and ovarian cancer associated with such mutations).
3. See Francis S. Collins, BRCAI-Lots of Mutations, Lots of Dilemmas, 334 NEw ENG. J.
MED. 186, 187 (1996) (stating that forthcoming studies regarding the BRCA1 mutation may
produce answers as well as citing the need for legislation to forbid the use of genetic information
in determining health insurance coverage).
4. HOLTZMAN, supra note 1, at 232-37 (arguing that employing scientific justification for
testing will limit harms).
5. Benjamin S. Wilfond & Kathleen Nolan, National Policy Development for the Clinical
Application of Genetic Diagnostic Technologies: Lessons From Cystic Fibrosis, 270 JAMA 2948,
2948-49 (1993) (explaining that appropriate procedural mechanisms should be established at both
state and federal levels to prevent the unnecessary confusion, expense, and personal or social
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that the decision to screen must be based on scientific evi-
dence.
Above all, it must be determined, based on review of the
evidence and consultation with experts, whether the testing
technology is sufficiently well validated before it is offered to
the public. Screening tests, like drugs, must be "safe and effec-
tive" before they can be marketed.
To ensure safety, effectiveness, and necessity, federal and
state public health agencies must ensure that screening tests
satisfy reasonable criteria.6 First, the disorder to be screened
must be a significant public problem. Hereditary breast cancer
certainly qualifies on this account. In 1995, there were an
estimated 185,700 new cases of breast cancer; thirty-one per-
cent of those were new cancers in women. Based on the esti-
mated new cases of breast cancer, there will be approximately
44,560 deaths; this constitutes seventeen percent of total cancer
deaths in women. Only lung cancer exceeds breast cancer as a
contributor to cancer deaths in women.7 In fact, one out of
every eight women will be affected by cancer by age ninety-
five.'
Second, a sufficiently reliable screening test must be made
available. To date, screening for hereditary breast cancer has
failed to meet this criteria. If the purpose of the test is to an-
swer the question "which individuals in the screened popula-
tion have a specific mutation?" then the available molecular
tests would have a high degree of accuracy. This is because the
chance of misidentification of the genetic haplotype is very
small. However, mutation identification and the actual expres-
harms likely to result from a completely unrestrained application of developing genetic technolo-
gies and that these procedural mechanisms should be based on the evidentiary model).
6. See COMM. FOR THE STUDY OF INBORN ERRORS OF METABOLISM, NATIONAL
ACADEMY OF SCIENCES, GENETC SCREENING: PROGRAMS, PRINCIPLES, AND RESEARCH (1975)
(providing information about a variety of principles, procedures, and problems connected with
genetic screening); Neil A. Holtzman, Genetic Screening: Criteria and Evaluation-A Message for
the Future, in GENETc DISEASE: SCREENING AND MANAGEMENT 3, 3-10 (Thomas P. Carter &
Ann M. Willey eds., 1986) (explaining that criteria for genetic screening can seldom be satisfied;
therefore, expansion of screening has been limited).
7. See Sheryl L. Parker et al., Cancer Statistics, 1996, 46 CANCER 5, 19 (1996)
(providing a table which demonstrates women's death-rate from various types of cancer).
8. See AMERICAN CANCER SOCIETY, CANCER FACTS AND FiGuRES-1996, at 13 (1996)
(discussing estimates of total U.S. cancer cases diagnosed in 1996, as well as probabilities for
developing invasive cancers at certain ages).
19971
HEALTH MATRIX
sion of malignancy are not synonymous. Thus, a reliable
screening test must be developed.
To develop a reliable screening test, multiple hurdles must
be crossed. Over 100 mutations of BRCA1 and dozens of
mutations of BRCA2 have been identified. Correlation of these
genotypes to phenotypic expression is in progress. To ensure
the reliability of these predictions, there must be proper docu-
mentation.9 Additionally, detection rates are incomplete unless
a whole series of genetic studies are included in the test panel.
To detect the known forms of hereditary breast cancer likely
would require tests for BRCA1, BRCA2, ataxia telangiectasia,
HER-2/neu and p53. Even with all of these precautions, many
women with cancer-associated mutations still will not be
identified.
Presently, studies are in progress which will allow better
estimates of screening parameters. For example, the frequency
of a false positive or negative result and estimates of positive
predictive value must be determined. A hurdle which must be
faced in this arena is that the definition of a positive test is
confounded by the variable existence or expression of the gene.
Finally, even after correctly detecting the presence of a muta-
tion, there is only a probablistic likelihood of the actual ex-
pression of malignancy.' ° In screening terminology, this could
be called a false screening positive for the women who have a
mutation but are spared by failure of expression, or who have
mutations which do not lead to an increased risk of cancer.
Third, there needs to be a clear diagnostic test to separate
a true from a false positive. (In the case of testing for the
9. See Ruth Hubbard & R.C. Lewontin, Pitfalls of Genetic Testing, 334 NEw ENG. J.
MED. 1192, 1192 (1996) (stating that even in the case of so-called simple mendelian variations,
the relation between the DNA sequence of a gene and the corresponding phenotype is far from
simple). See generally Douglas F. Easton et al., Breast and Ovarian Cancer Incidence in BRCAI-
Mutation Carriers, 56 AM. J. HUM. GENEICS 265 (1995) (explaining that genetic linkage studies
have demonstrated that many families with dominant predisposition to early-onset breast cancer
or ovarian cancer are the result of a gene located on chromosome 17q21 although there is
significant evidence of heterogeneity of risk between families).
10. See Hubbard & Lewontin, supra note 9, at 1193 (stating that the fact that a woman
from a "cancer-prone" family tests positive for a cancer-linked DNA variant does not mean that
she will definitely have a tumor, even though her lifetime risk of breast cancer may be as high as
eighty-five percent, and that of ovarian cancer as high as forty-five percent); Easton et al., supra
note 9, at 270 (stating that the difference in ovarian cancer risk, between high-risk and low-risk
families, may have been exaggerated by the heterogeneity analysis).
[Vol. 7:31
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presence of a gene that increases susceptibility or risk, this
criteria does not apply). Typically, an initial positive screening
test can be confirmed by a "gold standard" diagnostic test. At
the time of the positive BRCA1 test result, the tested woman
may have no malignant cells. Only time and careful surveil-
lance with additional screening, like mammography, ultra-
sound, and ultimately biopsies, will validate the initial screen-
ing as a "true positive." Furthermore, these additional screening
mechanisms are not without fault. Whether or not a breast
examination and mammography will detect tumors is size re-
lated and increases with the age of a woman. Finally, the train-
ing and experience of the radiologist is also a variable fac-
tor." Thus, there is a need for more sensitive methods for the
early detection of actual malignancy.
Fourth, there must be effective intervention to prevent or
ameliorate the consequences of the disorder. Again, presently
there is no clearly effective intervention with hereditary breast
cancer. The effectiveness of existing options, such as dietary
changes, early detection, tamoxifen, and prophylactic breast
and ovarian surgery, is not clearly known or documented. 2
11. See Craig A. Beam et al., Variability in the Interpretation of Screening Mammograms
by U.S. Radiologists: Findings From a National Sample, ARCHIVES INTERNAL MED., Jan. 22,
1996, at 209, 213 (stating that current accreditation programs that certify the technical quality of
radiographic equipment and images, but not the accuracy of the interpretation given to
mammograms, may not be sufficient to help mammography fully realize its potential to reduce
breast cancer mortality); Joann G. Elmore et al., Variability in Radiologists' Interpretations of
Mammograms, 331 NEw ENG. J. MED. 1493, 1498 (1994) (stating that although the efficacy of
mammography in screening women for breast cancer is well-documented, radiologists can differ,
sometimes substantially, in their interpretations and recommendations for follow-up); Daniel B.
Kopans, The Accuracy of Mammographic Interpretation, 331 NEw ENG. J. MED. 1521, 1521
(1994) (stating that there is great variation among the expertise of radiologists).
12. See Malcolm M. Bilimoria & Monica Morrow, The Woman at Increased Risk for
Breast Cancer: Evaluation and Management Strategies, 46 CANCER 263, 263 (1995)
(demonstrating the difficulty in evaluating the efficacy of prophylatic mastectomy); Karla
Kerlikowski et al., Should Women with Familial Ovarian Cancer Undergo Prophylatic
Oophorectomy, 80 AM. J. OBSTETRICS & GYNECOLOGY 700, 701 (1992) (evaluating the
effectiveness of prophylatic surgery for women with a family history of ovarian cancer); NIH
Consensus Development Panel on Ovarian Cancer, Ovarian Cancer: Screening, Treatment, and
Follow-up, 273 JAMA 491, 491 (1995) (stating that current screening modalities to reduce
mortalities from ovarian cancer still leave some uncertainty as to their effectiveness); Joyce A.
O'Shaughnessy, Chemoprevention of Breast Cancer, 275 JAMA 1349, 1349-53 (1996)
(summarizing findings about the incidence of breast cancer, indicators of risk, current treatment
options and effectiveness, and the status and direction of research); Mary-Claire King et al.,
Inherited Breast and Ovarian Cancer: What Are the Risks? What Are the Choices?, 269 JAMA
1975, 1979 (1993) (stating that the choices available to women with inherited risk are surveillance
and surgery with the Tamoxifen Prevention Trial available for some high-risk women); Kent F.
1997]
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Fifth, there must be resources, such as facilities and staff
available, to provide before and after test counseling, test inter-
pretation, and any other necessary interventions. These resourc-
es exist to a limited extent, as illustrated by the fifty-four Na-
tional Institute of Cancer designated centers. However, these
centers need to be clearly identified and organized into an
effective follow-up network. 3
Sixth, both health care providers and the population to be
screened must accept the screening system as worthwhile and
practical. This does not appear to be a substantial barrier as
there already appears to be a general acceptance of susceptibili-
ty screening."
Last, the screening must be cost beneficial and cost effec-
tive. Cost benefit methodologies have been developed for
cancer, 5 but need to be applied to specific screening designs.
The following statistics illustrate the wide range in cost with
Hoskins et al., Assessment and Counseling for Women with a Family History of Breast Cancer: A
Guide for Clinicians, 273 JAMA 577, 584 (1995) (stating that there is a need for primary care
clinicians to be able to assess familial risk factors for breast cancer, provide individualized risk
information, offer counseling to high-risk individuals, and offer surveillance recommendations),
13. See Harry Campbell et al., The Future of Breast and Ovarian Cancer Clinics: No Lon-
gerJustResearch-Now a Clinical Need, 311 BRIT. MED. J. 1584, 1584 (1995) (recommending the
development of standardized practices and nationally coordinated research for regional cancer
clinics, funded by research agencies, to offer screening, information, and counseling).
14. See D. Gareth Evans, Genetic Testing for Cancer Predisposition: Need and Demand,
32 J. MED. GENETics 161, 161 (1995) (stating that while screening for cancer is not fully
accepted, most cancer genetics clinics would offer screening to those at high-risk); Hemasree
Chaliki et al., Women's Receptivity to Testing for a Genetic Susceptibility to Breast Cancer, 85
AM. J. PUB. HEALTH 1133, 1134(1995) (indicating that the percentage of women participating in
the survey who stated that they would accept the test was remarkably high, considering the
threatening nature of a positive result); S. Mohammed et al., Attitudes to Predictive Testing for
BRCA1, 32 J. MED. GENETICS 140, 140 (1995) (stating that 81% of women surveyed indicated a
desire to undertake testing); Hemasree Chaliki et al., Women's Receptivity to Testing for a Genetic
Susceptibility to Breast Cancer, 85 AM. J. PUB. HEALTH 1133, 1134-35 (1995) (explaining that
90% of approximately one thousand patients are willing to be tested for genetic susceptibility to
breast cancer).
15. See Mary S. Baker et al., Estimating the Treatment Costs of Breast and Lung Cancer,
29 MED. CARE 40,41 (1991) (describing a general methodology in which the researcher estimates
the costs attributable to the cancer as the difference between the cost of caring for individuals with
cancer and the cost of caring for comparable individuals without cancer); Ruth Etzioni et al.,
Estimating the Costs Attributable to a Disease with Application to Ovarian Cancer, 49 J.
CLINICAL EPIDEMIOLOGY 95, 95 (1996) (focusing on the methods for estimating the average
present value of the medical costs attributable to a disease, and more specifically on handling
incomplete or censored cost and survival data and incorporating discounting); Herman Kattlove et
al., Benefits and Costs of Screening and Treatment for Early Breast Cancer: Development of a
Basic Benefit Package, 273 JAMA 142, 142 (1995) (indicating that by choosing which services
healthcare professionals provide to specific groups of patients, providers can substantially reduce
their expenses and still provide quality health benefits).
[Vol. 7:31
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various cancer screening mechanisms: The cost of the molecu-
lar analysis is between $150 and $1600 depending on the par-
ticular molecular test employed. Counseling and clinical servic-
es range from $200 to $300 per patient. A mammography costs
approximately $90 per test. Prophylactic surgery and recon-
struction costs range from $10,000 to $40,000. Finally, the
costs of public and professional education and organization still
needs to be determined. Until we have more information on the
cost and effectiveness of the individual elements of the
screening protocol and intervention, cost benefit and effective-
ness cannot be assessed.
Only the government is charged with public protection and
provided the tools of law and regulation to enforce its policies.
Thus, public health practitioners must educate those who im-
plement law and regulation. The scope of the problem is such
that even if ninety percent of health care professionals were
familiar with and voluntarily observed the general policy state-
ments and practice guidelines of professional organizations like
the American College of Medical Genetics, the American So-
ciety of Human Genetics (ASHG), 6 the Working Group on
Ethical, Legal, and Social Implications of the Human Genome
Project (ELSI), the Hereditary Susceptibility Working Group of
the National Action Plan on Breast Cancer, 7 and the National
Advisory Council for Human Genome Research,"8 inadequate
and premature testing programs would still pose a substantial
problem. Likewise, even if most third-party payors voluntarily
accepted, without modification, these pronouncements as the
standard of care, there would still be a substantial problem
16. American Society of Human Genetics, Statement of the American Society of Human
Genetics on Genetic Testing for Breast and Ovarian Cancer Predisposition, 55 AM. J. HuM.
GFaNriCS i, i (1994) (emphasizing that it is premature to offer screening until the risks associated
with BRCAI mutations are determined and the best strategies for monitoring and prevention are
accurately assessed).
17. American Society of Clinical Oncology, Statement of the American Society of Clinical
Oncology: Genetic Testing for Cancer Susceptibility, 14 J. CLINICAL ONCOLOGY 1730, 1730
(1996) (recognizing that cancer specialists must be fully informed of the issues associated with
genetic testing for cancer risk, the American Society of Clinical Oncology recommends that
cancer predisposition testing be offered only in limited circumstances).
18. National Advisory Council for Human Genome Research, Statement on Use of DNA
Testing for Presymptomatic Identification of Cancer Risk, 271 JAMA 785, 785 (1994) (stating
that it is premature to offer testing of either high-risk families or the general population as part of
general medical practice until crucial questions have been addressed).
1997]
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with premature and poorly designed commercial and private
testing programs.
The government also has the role of balancing competing
interests in order to ensure the best public policy. For example,
there are a number of "stake holders" with respect to screening
for hereditary breast cancer. These include women, high-risk
families, academic researchers, commercial test developers,
primary care providers, third-party payers, and genetic special-
ists. The government must balance all of these interests when
adopting a public policy regarding screening for hereditary
breast cancer.
George Annas"9 has compared the Medical Model, the
Market Model, and the Regulatory Model with respect to an
analogous problem; prenatal diagnosis. Under the Medical
Model, physician specialty groups decide when a test should
and should not be offered. However, the Medical Model has
been undermined by the Market Model in the interest of third-
party cost containment and the fear of malpractice. The Market
Model considers susceptibility testing as a profit-producing
product. Third-party payors will, therefore, control when,
where, and how testing is offered based on the definitions of
medical necessity and cost avoidance. Annas concludes that
more government regulation is inevitable. This is consistent
with Alexander Morgan Capron's theory of "creative preserva-
tion" which he defines as "a positive and original effort to en-
hance important values and relationships, rather than either a
negative (and probably futile) attempt to forestall use of the
biomedical technique or a resigned acquiescence in its undesir-
able changes.' 20
Based on the above-stated theories, I urge that we support
public agencies in the implementation of the consensus recom-
mendation of the genetic community. Thus, our goal is to
employ legal means to limit the offering of susceptibility test-
ing for hereditary cancer to only those health facilities which
19. See George J. Annas, Noninvasive Prenatal Diagnostic Technology: Medical Market or
Regulatory Model?, ANNALS N.Y. ACAD. SCI., Sept. 1993, at 262, 264 (comparing three models
on role of noninvasive prenatal diagnosis).
20. See Alexander Morgan Capron, The New Reproductive Possibilities: Seeking a Moral





The inherent authority of a government to impose restric-
tions on private rights for the sake of public health, welfare,
order, or security is defined as police power. In fulfilling gov-
ernmental responsibilities to protect the physical and mental
health as well as the welfare of its citizens, state health agen-
cies have the duty, when presented with facts that identify a
serious risk in this regard, to use their police powers even if
the action violates certain rights. The police power of a sov-
ereign state is a plenary power which need not be expressly
stated." Consideration of the established facts and knowledge
with respect to the societal implications of screening for breast
cancer susceptibility identifies a situation where this duty
arises. I concur with the position of Angus Clarke that
"programmes of population screening for genetic susceptibility
to disease should not be introduced, sponsored, managed, or
promoted by commercial corporations without strict
regulation."'  I therefore propose that the following statutory
language be adopted:
Every person and institution must be prohibited from offering
or providing tests to analyze genetic material with the intent to
determine the presence of genes which are associated with, or
are claimed to be associated with, breast cancer, unless the
person or institution is approved by the state agency to provide
such testing.
Because our society emphasizes the values of liberty and
autonomy, the use of the state's police powers is often chal-
lenged. Any such regulation which restricts liberty and autono-
my must, therefore, be defensible in a court of law. I will try
to respond to the arguments that could be brought against such
a strict implementation of the state's police powers.
What rights are violated? The highest order of rights are
fundamental rights guaranteed in the Constitution, thus, the
state bears a heavy burden to justify their violation. Opponents
21. See Jacobson v. Massachusetts, 197 U.S. 11, 24-5 (1905) (discussing the powers of the
state legislature to protect public health and safety within the context of compulsory vaccination
laws).
22. Angus Clarke, Population Screening for Genetic Susceptibility to Disease, 311 BRrr.
MED. J. 35, 37 (1995) (stating that evaluating such testing should include psychosocial and
medical outcomes for both high and low-risk individuals).
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of strict regulation of genetic screening may allege that there
has been a violation of the Fourteenth Amendment's liberty
rights. The argument may be made that the rights of health
care providers to provide care is being abridged. Health care
providers' right to practice their trade in general, to earn a
living, or make a profit are not significantly impaired by genet-
ic screening regulations. Providers are only prevented from
taking specific actions regarding genetic screening that they
may want to take. However, the rights of health care profes-
sionals are in many instances subject to such prohibitions.
Numerous examples, such as licensing requirements and busi-
ness and professional regulations, restrict the actions of health
care professionals. Moreover, the statutory language that I
propose does not totally prohibit the action, such as laws pro-
hibiting murder and theft. Rather, the proposed language mere-
ly requires that certain conditions be satisfied before the genet-
ic screening is permitted. My proposal is, therefore, more anal-
ogous to such laws as those which require an operator's license
to drive a car.
Let us assume for the sake of argument that a court would
accept the right of health care providers to offer a BRCA1 test.
Let us also assume that the public's right to obtain a BRCA1
test is legally established. Furthermore, let us assume that both
the right to provide and the right to receive a BRCA1 test are
fundamental rights. Courts have upheld the constitutionality of
state laws. which infringe on fundamental rights under the
following conditions: first, the state must demonstrate that
there is a compelling state interest that is sufficiently strong to
justify the law; second, the state must demonstrate that no less
intrusive or restrictive measures are available; and finally, the
state must demonstrate that the law is reasonably expected to
achieve the state's objective.
The language that I have proposed is drafted in a similar
manner as a licensing law. There is a body of jurisprudence
that validates the legitimacy of state licensing procedures. For
state licensing procedures to be adopted, the state must estab-
lish that the regulation of that activity, in this case the screen-
ing for hereditary breast cancer, is necessary. Thus, the state
must cite evidence which demonstrates that in the absence of
such regulation there is a real potential for harm to the public.
[Vol. 7:31
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Unregulated screening for breast cancer genes clearly
threatens serious harm to the persons tested, their families, and
society in general. The first potential harm is the failure of
physicians to be provided with, and/or to communicate to
potential testees, sufficient objective and valid information
about hereditary breast cancer screening. Testees must be in-
formed of the risks and benefits of testing, as well as the cur-
rent limitations on our knowledge of the consequences of po-
tential interventions.
Second, unregulated screening of hereditary breast cancer
could lead to faulty, or negligent DNA analysis, for example,
reporting that the BRCA1 haplotype is present when in actuali-
ty it is absent. This inaccurate diagnosis would result in unnec-
essary mental anguish, unnecessary, risky, costly, and mutilat-
ing interventions, and the unnecessary expenditure of public
and private funds.
A third and more likely harm that could result from unreg-
ulated screening of hereditary breast cancer is the anxiety
caused by the probabilistic nature of the association of the test
results with clinical disease in the tested woman and in her
family. Counseling and interpretation of the test results require
special knowledge and skills not universally available in the
health care community.' Errors of commission and omission
could lead to the same kinds of adverse consequences as those
discussed above.
Fourth, unregulated testing for heredity breast cancer has
the potential to generate paranoia about breast, ovarian, and
prostate cancer. This could result in a significant increase in
the cost of health care due to an increased frequency of physi-
cian visits, mammography, vaginal ultrasound, blood tests, and
surgery. Moreover, much of this increased intervention would
probably prove to be unnecessary and counterproductive.
23. See Hoskins et al., supra note 12, at 582 (stating that DNA-based predictive testing is
not commercially available, nor is it available as a service in hospital-based clinical laboratories);
Barbara B. Biesecker et al., Genetic Counseling for Families with Inherited Susceptibility to
Breast and Ovarian Cancer, 269 JAMA 1970, 1970 (1993) (stating that large scale population
screening for BRCAI mutations is likely to become a reality in the next few years, but is currently
limited to very rare cases); Henry T. Lynch & Patrice Watson, Genetic Counselling and
Hereditary Breast/Ovarian Cancer, 339 LANcET 1181, 1181 (1992) (stating that physicians must
learn how to interpret molecular genetic and gene linkage findings, and how to provide genetic
information and management recommendations to those at high risk).
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Finally, unregulated screening for hereditary breast cancer
poses the distinct possibility that positive individuals will be
subjected to discrimination in employment and insurance in
order to avoid these costs. States have compelling interests in
preventing these adverse consequences that threaten public
health and welfare.
Just as critics of highly regulated screening might argue
that their liberty rights are being violated, likewise they also
may argue that limiting testing to approved centers or person-
nel is an unlawful restraint of trade. Though the right to prac-
tice a trade or earn a living is not a fundamental right, this
objection has been raised against various licensing laws in the
past.
The legislative intent of anti-monopoly law is to promote
competition so as to (1) ensure a variation in the quality of
product or services; and, (2) encourage variation in prices
which are desirable to a society of consumers. Alternatively,
the legislative purpose might be to protect an individual's right
to engage in commerce and be oriented to assist commercial
vendors.
The statutory restrictions that I propose do not violate any
of these objectives of anti-monopoly law. The law guarantees a
minimal quality of services. Variation in quality of health care
should not be so excessive as to include substandard services
that do more harm than good or that are a threat to public
health. The quantity and quality of services will not be limited
once the minimum standard is achieved. There is no monopoly
unless only one person or one facility is qualified. Thus, choice
of vendor is preserved.
With respect to price control, the existence of multiple
approved centers will contribute to price competition. However,
given the major players in current health care, mainly third-
party payors, the state, managed care plans, and insurance
companies, there is legal recognition of the concept of price
restriction.
Finally, the right of providers to offer testing is not abso-
lute, but is conditioned on meeting certain reasonable and nec-
essary standards. The state has no obligation to any individual
to guarantee their right to any particular trade or to economic
success at that trade.
[Vol. 7:31
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Therefore, I argue that restraint of trade as a result of the
statutory language that I propose is minimal and insignificant. I
further argue that any restraint of trade that may result is justi-
fiable in terms of the greater countervailing state interest in the
protection of public health. Finally, if the testing program is
organized as a state health agency project, with the providers
operating as agents of the state, the providers actually would
be exempt from restraint of trade requirements.
In addition to establishing a compelling state interest, the
state must demonstrate that there is no less intrusive means of
protecting the public that would not require regulation. While
public and professional education can be promoted, only a law
can provide assurance that suggested standards will be fol-
lowed. Diagnostic tests are currently regulated by the Food and
Drug Administration (FDA). Before marketing the test, the
developer must demonstrate to the FDA that the test is safe
and effective for the purposes for which it will be marketed. In
the case of tests for cancer susceptibility, this will be a time
consuming and costly procedure. Moreover, it is not likely that
in the immediate future developers will be able to demonstrate
that screening mechanisms for hereditary breast cancer are safe
and effective. In addition, the FDA does not presently regulate
the environment of the clinical services which would be re-
quired to avoid the adverse consequences described. Therefore,
reliance on FDA regulations would not be a more effective but
less intrusive alternative.
The State of California followed this highly regulated
model for Maternal Serum Alpha Feto-protein testing. Labora-
tories were prohibited from testing until the state developed
regulations to ensure that the benefits exceeded the risks. A
program of professional and public education was developed
and implemented. Informed consent was a mandatory require-
ment. Laboratory testing was limited to qualified and moni-
tored, private laboratories which provided high quality services
based on competitive bids. Post-test follow-up was provided in
private, state approved, multi-disciplinary centers that were
experienced in prenatal diagnosis. Costs were distributed across
the whole population by the use of a single participation fee.
Data were collected and the program policies were continually
evaluated. Based on this public/private approach, women from
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California got earlier and better access to high quality testing
than women in states where testing was unorganized and un-
regulated.
I would propose a similar approach for breast cancer
screening. General offering of the test to the population of
women from California should be prohibited, until, with the
help of an expert advisory committee, which includes all of the
stakeholders, the Department of Health Services has deter-
mined to whom, when, where, and how the test can be provid-
ed as a net benefit. I cannot anticipate the results of the delib-
erations of the advising panel. However, I can speculate on
what the regulations would do.
I have diagramed what I perceive to be a general model of
a breast cancer screening program in Figure 1. The first task is
to develop a method for identifying a high-risk population.
Presently, there are several good models for risk assessment
which could be implemented.24 Additionally, primary care
physicians must be trained in the application of the risk algo-
rithm. If women are identified as being in the high-risk catego-
24. See Kenneth Offit & Karen Brown, Quantitating Familial Cancer Risk: A Resource for
Clinical Oncologists, 12 J. CLINICAL ONCOLOGY 1724, 1733 (1994) (stating that multidisciplinary
cancer genetic counseling is an emerging resource available to physicians who care for families
with common adult malignancies); Mitchell H. Gail et al., Projecting Individualized Probabilities
ofDeveloping Breast Cancer for White Females Who Are Being Examined Annually, 81 J. NAT'L
CANCER INsT. 1879, 1879 (1989) (describing a model of relative risks for various combinations of
age at menarche, age at first live birth, number of previous biopsies, and number of first-degree
relatives with breast cancer as developed from case-control data from the Breast Cancer Detection
Demonstration Project); Elizabeth B. Claus et al., Age at Onset as an Indicator of Familial Risk of
Breast Cancer, 131 AM. J. EPIDEMIOLOGY 961, 972 (1990) (investigating a large population-
based, case-control study conducted by the Centers for Disease Control which determined that
family and age at onset were the only risk factors strongly associated with familial risk of breast
cancer); Diana Eccles et al., Genetic Epidemiology of Early Onset Breast Cancer, 31 J. MED.
GENEICS 944, 946 (1994) (stating that the parameters of the genetic model were estimated by
maximizing the likelihood of the observed phenotypes in families using joint and conditional
likelihoods); Deepthi de Silva et al., Identification of Women at High Genetic Risk of Breast
Cancer Through the National Health Service Breast Screening Programme (NHSBSP), 32 J.
MED. GENETICs 862, 865 (1995) (discussing the first attempt in England at a population-based
study to assess the incidence of familial breast cancer and offer genetic counseling for those at
greater than twice the age related risk of breast cancer); Elizabeth B. Claus et al., Genetic Analysis
of Breast Cancer in the Cancer and Steroid Hormone Study, 48 AM. J. HUM. GENETICs 232, 241
(1991) (describing a unique study which determined whether various genetic models fit to an
observed data set and then calculated the expected age-specific risk of breast cancer under a given
genetic model and compared them with the age-specific risk); David E. Anderson & Michael D.
Badzioch, Risk of Familial Breast Cancer, 56 CANCER 383, 384 (1985) (discussing a model which
develops probabilities of developing breast cancer from three pedigree groups: sisters of patients
whose mothers, sisters, or second-degree relatives had previous breast cancer).
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ry, they would be referred to approved Breast Cancer Screen-
ing Centers. There are several models in this area as well
which could be implemented. For example, there are a core of
cancer specialty clinics and National Institute for Health recog-
nized cancer centers which could be developed to meet this
need. At the Breast Cancer Screening Centers, pre-test counsel-
ing would be required to frankly and honestly share the unsat-
isfactory state of our knowledge about detection rate, sensitivi-
ty, specificity, costs, conditional interpretation of risks and
known effectiveness of interventions.
Figure 1
Primary Care Selection of High Risk Women
Referred
State Approved
Cancer Genetics Counseling Center
PreTest Genetic Counseling
Psychological Services
Decline Tests 0 1,0. Informed Consent State Approved




Test Results -.- Test Interpretation
State Approved






Radiology - mammograrn, vaginal ultrasound
Oncology - tamoxifen
Surgery - prophylactic mastectomy, oophorectomy
Life style changes - diet, etc.
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After informed consent, testing would be permitted in
quality controlled laboratories directed by a molecular biolo-
gist. This molecular biologist would be familiar with the rapid-
ly developing field of mutation and linkage analysis. The labo-
ratory would be prepared to offer cancer-related tests which
include BRCA1, BRCA2, p53, HER-2/neu. Post-test counseling
would be provided and patients would have additional access
to oncologic specialists such as surgeons, radiologists, and
oncologists, and mental health professionals. These approved
Breast Cancer Screening Centers would also have a research
function and would collect data on testing outcomes, interven-
tion decisions, and long-term follow-up and observations.
This scheme has the advantage of providing monitored
high quality clinical and laboratory services to a select high-
risk population. By organizing data collection, it would contrib-
ute to the ultimate resolution of the predictive screening prob-
lem. It also addresses the issue of equitable access by provid-
ing objective information to all high-risk women. By control-
ling costs, the technology would no longer be limited to the
rich. The scheme also has the benefit of providing a forum,
with participation by the women most directly affected, which
would debate public policy development rather than blindly
adopt policies provided by proprietary programs.
There are several reasons why this model is superior to
commercial-based programs. First, commercially based pro-
grams have a vested interest in promoting wide-scale testing
and, therefore, are less likely to provide complete and objective
information about screening. In contrast, regulated programs
can insist on adequate public education and consent. Second,
commercial third-party payers may develop policies
disproportionately weighted toward cost containment rather
than high quality care. Therefore, if such a program is ap-
proved, it should be mandatory that third-party payers cover
the costs for their high-risk eligibles.
The numerous workshops, articles and statements pro-
duced by ELSI, The Human Genome Advisory Council, and
others in this area are mainly directed toward research pro-
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grams, investigators and Institutional Review Boards. Attention
must now be directed towards clinical practice.
In the absence of a governmental regulation, premature
offering of testing is not only a potential problem, it is highly
likely. In fact, two commercial firms, OncorMed and Myriad
Genetics Inc.,' are showing every sign of promotion of test-
ing in the absence of clear guidelines and protocols. These
commercial firms have not heeded the recommendations of the
genetic experts and concerned women.
Unrestricted marketing of screening for hereditary breast
cancer raises issues of equitable access. Will only the affluent
have access? Will third-party payors cover the test? In all
likelihood, some will and some will not. Likewise, some will
cover only laboratory costs, but will not cover the costs of
equally important counseling interventions. What is the poten-
tial impact on the economics of health care? What are the
implications for discrimination by insurers based on member-
ship in high-risk groups, for example, Jewish women, or test
results or family history?
A government-regulated program conducted in the private
sector, while not able to provide completely satisfactory an-
swers to these questions, has the ability to provide a better
response than uncontrolled private provision of testing.
The media can contribute positively or negatively to this
problem. By reporting new discoveries they raise expectations.
By publicizing the commercial availability of tests, the media
can create a demand for testing. However, by carefully report-
ing the limitations of current testing and knowledge, they can
contribute to informed participation by the public in the forma-
tion of policy.
Lastly, I would like to speculate on possible future appli-
cations of information being developed by the large group of
talented people working on this problem. BRCA1 produces a
tumor-suppressing protein which might provide a key to
screening for nonhereditary forms of breast cancer. Tests for
25. See Rachele Kanigel, Breast Cancer Test Greeted By Criticism, Concern, OAKLAND
TRIB., Jan. 13, 1996, at AI (discussing a blood test offered by a Maryland biotechnology company
which will locate mutations in the BRCAI gene); Natalie Angier, Surprising Role Found for
Breast Cancer Gene, N.Y. TIMES, Mar. 5, 1996, at CI (stating that Myriad Genetics Inc. has
submitted a patent on the gene).
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abnormal protein production such as protein truncation appear
to be an effective and less costly screening technique.26 Rather
than using molecular techniques, we may be able to use a
protein transcription translation, biochemical or
immunochemical assay, for altered gene product which is more
directly related to malignancy. Such a development could re-
place or supplement the current inadequate screening methods
such as self-examination and mammography. It might even
lead to more effective therapy.
26. See Pauline A.M. Roest et al., Protein Truncation Test (P7T) for Rapid Detection of
Translation-Terminating Mutations, 2 HuM. MOLECULAR GENETICs 1719, 1719 (1993)
(discussing a rapid and sensitive method, the PTT, which is based on a combination of RT-PCR,
transcription and translation, and selectively detects translations-terminating mutations); Alex M.
Garvin et al., Informed Consent and BRCA1 Mutation Detection in Archived Breast Tumour
Specimens, 347 LANCET 1189, 1189 (1996) (stating that 52% of all BRCA1 mutations are
detectable by the protein truncation test of exon eleven).
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